Serving To Educate Primary Care Clinicians On Metabolic Issues
Evidence Based Medicine Header 1
Medical Education Header 2
Metabolic Diseases Header 4

Non-CME Educational Activities

Recognition and Management of Hypoglycemia
Jay H Shubrook, DO, FAAFP, FACOFP
“Hypoglycemia is the major limiting factor in the glycemic management of type 1 and type 2 diabetes.” —American Diabetes Association

Overweight: The Overlooked Risk Factor
Robert F. Kushner, MD; Craig Primack, MD, FACP, FAAP, FOMA
Thirty percent. That’s the estimated projected prevalence of adults with overweight in the United States in 2030.1 Overweight, also called pre-obesity, is defined as having a body mass index (BMI) from 25.0 to <30.0 kg/m2 . Thirty percent is actually a reduction from the 33.1% of US adults who had overweight in 1988-1994 and the 31.6% in 2015-2016.

Current and Emerging Issues in the Management of Heart Failure in Primary Care
Robert Chilton, DO, FACC; Stephen Brunton, MD, FAAFP
Heart failure (HF) is a debilitating, often fatal disease that results in major health and socioeconomic consequences. The 5-year mortality rate for HF is similar to many types of cancer, eg, prostate, bladder, and colorectal cancers in men, and breast, colorectal, and ovarian cancers in women.1 Far exceeding hospitalizations for heart attack, coronary artery disease, or atrial fibrillation, HF was the primary diagnosis for 978,135 hospitalizations in the United States in 2014.2

Case Studies in Hyperlipidemia
Michael Cobble, MD, FNLA
In this article, I provide suggestions for identifying patients classified as “intermediate risk” for preventive care. According to the American College of Cardiology (ACC)/ American Heart Association (AHA), these patients have a 10-year ASCVD risk score of =7.5% to <20%, but because of the presence of risk-enhancing factors, have a higher overall ASCVD risk.3

A Practical Approach to Managing Heart Failure in Type 2 Diabetes Mellitus
Javed Butler, MD; Pamela Kushner, MD
HEART FAILURE IN DIABETES MELLITUS The treatment of patients with T2DM has generally focused on lowering the blood glucose, specifically the A1c, to 7% or lower (or some other individualized goal).

Evolving Issues in Statin Selection
Michael Cobble, MD, FNLA
Statin therapy is the pharmacologic cornerstone for reducing low-density lipoprotein cholesterol (LDL-C) and preventing or slowing progression of atherosclerotic cardiovascular disease (ASCVD).1

Advances in Type 2 Diabetes
Jay H. Shubrook, DO, FAAFP, FACOFP
Advances in Type 2 Diabetes: Focus on Basal Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy